Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347843 | 0.83 | TP53 (0.40) | CYP3A4CYP1A2ADRB2ADRB1ADRB3 | |
| SCHEMBL1063692 | 0.83 | ALDH1A1 (0.39) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL3381395 | 0.81 | CA12 (0.41) | CYP3A4ALDH1A1CYP1A2SMN1; SMN2HSD17B1 | |
| SCHEMBL2950028 | 0.81 | KCNN4 (0.50) | ALDH1A1KCNN4SMN1; SMN2POLBKDM4E | |
| SCHEMBL1498489 | 0.80 | KDM4E (0.46) | ALDH1A1SMN1; SMN2POLBKDM4ELMNA | |
| SCHEMBL3380455 | 0.80 | CA12 (0.42) | CYP3A4ESR1ESR2ALDH1A1ADRB2 | |
| SCHEMBL3381541 | 0.79 | PPARA (0.39) | SMN1; SMN2RAB9A | |
| SCHEMBL9360219 | 0.76 | LCK (0.38) | ALDH1A1KCNN4SMN1; SMN2NPC1POLB | |
| SCHEMBL6577199 | 0.75 | ALDH1A1 (0.46) | CYP3A4ESR1ESR2ALDH1A1ADRB1 | |
| SCHEMBL4607710 | 0.73 | CNR1 (0.53) | CYP3A4ESR1ESR2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474387-B1 | DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-24 | — | — | EP | disclosed |
| EP-1572180-B1 | USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-7375124-B2 | Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-20 | — | — | US | disclosed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | disclosed |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-13 | — | — | US | disclosed |
| EP-1572180-A1 | USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-14 | — | — | EP | disclosed |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P. A | 2005-03-10 | — | — | US | disclosed |
| EP-1474387-A2 | DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004056355-A1 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003059875-A2 | DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | PPARA, PPARD, PPARG | CYP3A4 1442/4885ESR1 1687/4885ESR2 433/4885 |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | LIPC, HMGCR, PNLIP | CYP3A4 1605/4885ESR1 4575/4885ESR2 1335/4885 |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | PPARG, PPARA, PPARD | CYP3A4 2541/4885ESR1 1999/4885ESR2 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.